We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01259856
First Posted: December 14, 2010
Last Update Posted: January 11, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Myeloproliferative Disorders-Research Consortium
National Cancer Institute (NCI)
Roche Pharma AG
Information provided by (Responsible Party):
Ronald Hoffman, Icahn School of Medicine at Mount Sinai
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: June 2017
  Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)